Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson's disease patients
Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson's disease patients
复制标题
帕金森病患者脑脊液hsa-miR-626变化的初步研究
DOI：
10.1016/j.jocn.2019.08.082
复制
发表时间：
2019-12-01
影响因子：
2
通讯作者：
Wang, Chun-yu
中科院分区：
文献类型：
--
作者：
Qin, Li-xia;Tan, Jie-qiong;Wang, Chun-yu
据报道，microRNA 可抑制肿瘤生长、侵袭和转移，并在神经退行性疾病中发挥作用。此外，在神经胶质瘤、阿尔茨海默病（AD）、帕金森病（PD）、多发性硬化症和抑郁症等中枢神经系统疾病患者的外周血、脑脊液（CSF）和脑组织中发现了microRNA的变化。与其他体液相比，脑脊液最能准确地反映大脑的病理过程。为了了解 PD 患者中 microRNA 表达是否失调，并进一步发现 PD 的潜在诊断生物标志物和有希望的治疗靶点，我们使用实时聚合酶链反应 (RT-PCR) 比较了 20 名 PD 患者、13 名 AD 患者和 27 名对照者的 CSF microRNA 与其他神经系统疾病（如脑炎和格林巴利综合征）。最后，我们发现与 AD 和对照组相比，PD 患者脑脊液中 hsa-miR-626 的平均表达水平显着降低。我们的方法有可能在脑脊液中识别出一种生物标志物，经过进一步研究，该生物标志物可以与其他帕金森病生物标志物结合用于帕金森病的检测、诊断和监测。 (C) 2019 Elsevier Ltd. 保留所有权利。
microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, changes in microRNAs are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues in patients of central nervous system diseases, including glioma, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis and depression. Compared with other bodily fluids, CSF is the most accurate at representing the pathological processes of the brain. To understand whether microRNA expression may be dysregulated in the patients of PD, and to further discover potential diagnostic biomarkers and promising therapeutic targets for PD, we used real-time polymerase chain reaction (RT-PCR) to compare CSF microRNAs from 20 PD patients, 13 AD patients and 27 controls with other neurologic disorders such as encephalitis and Guillain-Barre syndrome. Finally, we found that the mean expression level of hsa-miR-626 was significantly reduced in the CSF of patients with PD compared with AD and controls. Our approach potentially identified a biomarker in CSF that upon further investigation, could be used for the detection, diagnosis, and monitoring of PD in combination with other PD biomarkers. (C) 2019 Elsevier Ltd. All rights reserved.